ReviewNaunyn-Schmiedeberg's archives of pharmacology2026
NRF2 modulation in colorectal cancer chemoprevention: integrating traditional medicine with translational strategies against oxidative stress, inflammation, and cancer stem cells.
Review in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) is an important and significant reason for cancer-related morbidity and mortality globally. Treatment remains challenging due to recurrence, metastasis, and chemoresistance. Evidence shows that oxidative stress, ongoing inflammation, and cancer stem cells (CSCs) play essential functions in CRC development and progression. Nrf2 is a master regulator of cellular redox balance through the Keap1-Nrf2-is signalling pathway. Normal activation of Nrf2 protects colonic cells from oxidative DNA harm and inflammation during initial carcinogenesis. However, sustained Nrf2 activation in tumours encourages chemoresistance, metabolic reprogramming, and CSC upkeep, showing a dual role. Traditional medicine and dietary phytochemicals (curcumin, sulforaphane, resveratrol, EGCG, berberine) can modulate Nrf2 while interacting with NF-κB, Wnt/β-catenin, and Notch pathways. This review synthesises mechanistic and translational evidence on Nrf2 modulation in CRC chemoprevention, stressing conventional medicine-derived agents in modern approaches. It moreover highlights difficulties, limitations, and future viewpoints for precision chemoprevention and personalised interventions.
Indexed as
Identifiers
42919975What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.